SCHEMBL17145362

SCHEMBL17145362

NC(=O)C1CCC(CN2C(=O)CCC2=O)CC1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.38
HTR1A P08908 1/20 0.35
TDP1 Q9NUW8 2/20 0.34
GAA P10253 1/20 0.34
MEN1 O00255 1/20 0.34
APEX1 P27695 1/20 0.34
KMT2A Q03164 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ALDH1A1 P00352 3/20 0.34
PKM P14618 1/20 0.34
PLG P00747 1/20 0.33
PLAT P00750 1/20 0.33
LMNA P02545 1/20 0.33
BACE1 P56817 1/20 0.33
BACE2 Q9Y5Z0 1/20 0.33
ITGB3 P05106 1/20 0.32
ITGAV P06756 1/20 0.32
POLB P06746 1/20 0.32
RAB9A P51151 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23476597 1.00 SMN1; SMN2 (0.38) SMN1; SMN2HTR1ATDP1GAAMEN1
SCHEMBL16552327 0.84 PLG (0.47) SMN1; SMN2HTR1AGAAMEN1KMT2A
SCHEMBL535579 0.84 PLG (0.47) SMN1; SMN2HTR1AGAAMEN1KMT2A
SCHEMBL16964802 0.82 HTR1A (0.43) SMN1; SMN2HTR1AMEN1KMT2AALDH1A1
SCHEMBL10082604 0.82 HTT (0.37) SMN1; SMN2HTR1ALMNABACE1BACE2
SCHEMBL16072051 0.81 SMN1; SMN2 (0.37) SMN1; SMN2TDP1GAAMEN1APEX1
SCHEMBL744123 0.81 SMN1; SMN2 (0.37) SMN1; SMN2TDP1GAAMEN1APEX1
SCHEMBL24829512 0.81 HTR1A (0.35) SMN1; SMN2HTR1AKMT2AALDH1A1LMNA
SCHEMBL24287595 0.79 CYP1A2 (0.38) SMN1; SMN2MEN1KMT2AALDH1A1LMNA
SCHEMBL20056975 0.79 ALDH1A1 (0.38) SMN1; SMN2TDP1GAAMEN1APEX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019002875-A1 COMPOUNDS COMPRISING STAPLED OR STITCHED PEPTIDES FOR IMPROVED DRUG DELIVERY SUTURA THERAPEUTICS LTD (TC) 2019-01-03 WO disclosed
WO-2017109494-A1 BIOLOGICALLY ACTIVE COMPOUND CONJUGATED TO A STAPLED OR STITCHED PEPTIDE SUTURA THERAPEUTICS LTD (TC) 2017-06-29 WO disclosed
US-20160114052-A1 POTENT CONJUGATES AND HYDROPHILIC LINKERS IMMUNOGEN, INC. (US) 2016-04-28 US disclosed
US-9150649-B2 Potent conjugates and hydrophilic linkers IMMUNOGEN, INC. (US) 2015-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160114052-A1 POTENT CONJUGATES AND HYDROPHILIC LINKERS CD44, EPCAM, ABCG2 SMN1; SMN2 3022/4885HTR1A 3653/4885TDP1 2698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.